Cargando…

614. Evaluating the Use of Dalbavancin for Off-Label Indications

BACKGROUND: Dalbavancin (dalba) is a long-acting antibiotic (ABX) approved for skin and soft tissue infections. Post-marketing data suggests dalba is being used for off-label indications that require long term IV ABX; however, data assessing this off-label usage is limited. The purpose of this study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taylor, Katherine, Williamson, John, Stone, Tyler, Johnson, James, Gruss, Zachary, Luther, Vera, Russ-Friedman, Courtney, Ohl, Chris, Beardsley, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643763/ http://dx.doi.org/10.1093/ofid/ofab466.812

Ejemplares similares

Evaluating the Use of Dalbavancin for Off-Label Indications
por: Taylor, Katherine, et al.
Publicado: (2022)

51. Sustained Impact of an Antimicrobial Stewardship (AS) Initiative Targeting Asymptomatic Bacteriuria and Pyuria in the Emergency Department (ED)
por: Cash, Mary Catherine, et al.
Publicado: (2021)

838. Drivers of empiric carbapenem use: How important is history of extended-spectrum beta-lactamase (ESBL) infection?
por: Stone, Tyler J, et al.
Publicado: (2020)

1032. Evaluation of a Multiplex Rapid Diagnostic Panel in Respiratory Specimens from Critically Ill Patients with Hospital-Acquired Pneumonia
por: Erich, Bradley J, et al.
Publicado: (2021)

190. Promise and Pitfalls: Analyzing the Accuracy and Perceptions of Documenting Antibiotic Indication During Order Entry
por: Beardsley, James, et al.
Publicado: (2018)

118. Optimizing the management of coagulase-negative staphylococci (CoNS) contaminants by reporting the species name
por: Stone, Tyler J, et al.
Publicado: (2020)

Frequency of empiric antibiotic de-escalation in an acute care hospital with an established Antimicrobial Stewardship Program
por: Liu, Peter, et al.
Publicado: (2016)

2223. Evaluation of the Microbiology and Clinical Outcomes of Spontaneous Bacterial Peritonitis (SBP) within a US Academic Health System
por: Chris Parish, P, et al.
Publicado: (2023)

Sustained impact of an antibiotic stewardship initiative targeting asymptomatic bacteriuria and pyuria in the emergency department
por: Cash, Mary Catherine, et al.
Publicado: (2022)

184. Impact of the BioFire® FilmArray® Blood Culture Identification 2 Panel on Antimicrobial Treatment of Enterobacterales Blood Stream Infections
por: Logan, Ashley, et al.
Publicado: (2022)

Impact of a Stewardship Initiative to Decrease Treatment of Asymptomatic Bacteriuria and Pyuria in the Emergency Department
por: Smith, Jessica, et al.
Publicado: (2017)

607 Identification of Viral Infection Using a Polymerase Chain Reaction (PCR)-based Respiratory Virus Panel (RVP) Decreases Antibacterial Use
por: Rokas, Kristina, et al.
Publicado: (2014)

1877. Discrepant Susceptibilities Have Minimal Impact on Antibiotic Prescribing for Patients With Two or More Blood Cultures Positive for Coagulase-Negative Staphylococci
por: Smith, Jessica, et al.
Publicado: (2018)

2249. Impact of Minimum Inhibitory Concentration on Clinical Outcomes of Daptomycin for VRE Bloodstream Infection Among Neutropenic Oncology Patients
por: Caulder, Elisabeth, et al.
Publicado: (2019)

877. Synovial Fluid Testing Using the BioFire® Joint Infection (JI) Panel Potentially Decreases Time to Antibiotic Optimization for Acute Joint Infections
por: Whitt, Benjamin, et al.
Publicado: (2022)

1799. Impact of Real-Time Electronic Notifications to Pharmacists of Rapid Diagnostic Blood Culture Results
por: Caulder, Liz, et al.
Publicado: (2018)

Evaluation of the Potential Impact of a Multiplex Rapid Diagnostic Panel in Critically Ill Patients With Hospital-Acquired Pneumonia
por: Erich, Bradley J, et al.
Publicado: (2022)

Analysis of infections among patients with historical culture positive for extended-spectrum beta-lactamase (ESBL)–producing Escherichia coli or Klebsiella pneumoniae: Is ESBL-targeted therapy always needed?
por: Stone, Tyler J., et al.
Publicado: (2023)

A comparison of active versus passive methods of responding to rapid diagnostic blood culture results
por: Chandler, Elisabeth L., et al.
Publicado: (2022)

Clinical impact of a multiplex rapid diagnostic pneumonia panel in critically ill patients
por: Esplund, Jayda N., et al.
Publicado: (2023)

333. Clinical Impact of a Multiplex Rapid Diagnostic Panel in Critically Ill Patients
por: Esplund, Jayda, et al.
Publicado: (2022)

Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization
por: Simonetti, Oriana, et al.
Publicado: (2021)

The Impact of Diagnostic Stewardship on Clostridium difficile Infections
por: Bischoff, Werner, et al.
Publicado: (2017)

182. Piperacillin/tazobactam (P/T) versus meropenem (Mero) for treatment of extended-spectrum beta-lactamase (ESBL)-producing E.coli and K. pneumoniae bloodstream infections (BSIs)
por: Cox, Alexandra L, et al.
Publicado: (2023)

Treatment of Candida nivariensis Blood Stream Infection With Oral Isavuconazole
por: Randazza, Olivia, et al.
Publicado: (2022)

2765. Dalbavancin for challenging left ventricular assist device driveline infections
por: Doligalski, Christina, et al.
Publicado: (2023)

903. A Real-world Study Assessing the Risk of Lipid Changes and Other Metabolic Effects Associated with Integrase Inhibitor-based Antiretroviral Therapy
por: Gruss, Zachary, et al.
Publicado: (2021)

Dalbavancin
por: Barberán, José, et al.
Publicado: (2021)

Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant Staphylococcus aureus: A Retrospective Single-Centre Experience
por: Mazzitelli, Maria, et al.
Publicado: (2022)

Determination of a Tentative Epidemiological Cut-Off Value (ECOFF) for Dalbavancin and Enterococcus faecium
por: Weber, Robert E., et al.
Publicado: (2021)

Biologics in Dermatology: Off-Label Indications
por: Mitra, Debdeep, et al.
Publicado: (2020)

1004. Dalbavancin Use and Associated Cost-Savings: An Update
por: Streifel, Amber C, et al.
Publicado: (2022)

Dalbavancin: a novel antimicrobial
por: Chen, A Y, et al.
Publicado: (2007)

1132. Professional Development Curriculum for Fellows in Infectious Diseases
por: Wells, jessica B, et al.
Publicado: (2020)

1268. Dalbavancin for the Treatment of Infections due to Staphylococcus aureus
por: Streifel, Amber C, et al.
Publicado: (2020)

A case report of Nocardia spp. infective endocarditis in an injection drug user
por: Enwezor, Chukwunyelu, et al.
Publicado: (2021)

Less explored off-label indications of dexmedetomidine
por: Nair, Abhijit
Publicado: (2017)

122. Dalbavancin Use in Patients with Substance Use Disorders
por: Streifel, Amber C, et al.
Publicado: (2020)

1028. Dalbavancin Use in Complicated Infections and-associated Cost-Savings
por: Streifel, Amber C, et al.
Publicado: (2019)

2001. IDWeek Oral Abstract Coaching Pilot Program
por: Blyth, Dana, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sf69psk2poirqt98u3eq5tahre